DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Siefker-Radtke AO, Necchi A, Park SH. et al.
First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).
J Clin Oncol 2018;
36 (Suppl. 15) 4503
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.